» Articles » PMID: 8748103

Acute Stroke Treatment in UK Hospitals: the Stroke Association Survey of Consultant Opinion

Overview
Specialty General Medicine
Date 1995 Nov 1
PMID 8748103
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of the Stroke Association survey was to document United Kingdom consultant opinion of the immediate treatment for patients with acute stroke. A national postal survey of all UK hospital consultant general physicians, geriatricians and neurologist was carried out in 1992/3. We identified 1,953 consultants who routinely cared for patients with acute stroke; 39% of them regularly used aspirin for patients with acute stroke and 10% used low-dose subcutaneous heparin. Other treatments were rarely used. There was much uncertainty about the effectiveness of all currently available acute stroke treatments; 73% of physicians were prepared to start aspirin before a CT scan, but a much smaller proportion would start heparin therapy without one. Twenty-seven percent of consultants would actively treat hypertension in the initial 24 hours after stroke. Routine aspirin for secondary prevention after ischaemic stroke was widely accepted, but blood cholesterol lowering by drugs was not. In conclusion, aspirin and heparin alone are the only routinely used treatments for the immediate treatment of acute stroke; other treatments are used sparingly or not at all. The great uncertainty about the value of all available acute stroke treatments should encourage participation in randomised controlled trials.

Citing Articles

Primary prevention of first-ever stroke in primary health care: a clinical practice study based on medical register data in sweden.

Skaner Y, Nilsson G, Krakau I, Hassler E, Sundquist K Stroke Res Treat. 2010; 2010.

PMID: 20721332 PMC: 2915654. DOI: 10.4061/2010/468412.


Controlling hypertension immediately post stroke: a cost utility analysis of a pilot randomised controlled trial.

Wilson E, Ford G, Robinson T, Mistri A, Jagger C, Potter J Cost Eff Resour Alloc. 2010; 8:3.

PMID: 20331866 PMC: 2853505. DOI: 10.1186/1478-7547-8-3.


Drug therapy for acute ischaemic stroke: risks versus benefits.

Lindley R Drug Saf. 1998; 19(5):373-82.

PMID: 9825950 DOI: 10.2165/00002018-199819050-00004.

References
1.
Di Mascio R, Marchioli R, Tognoni G . From pharmacological promises to controlled clinical trials to meta-analysis and back: the case of nimodipine in cerebrovascular disorders. Clin Trials Metaanal. 1994; 29(1):57-79. View

2.
Sandercock P, Willems H . Medical treatment of acute ischaemic stroke. Lancet. 1992; 339(8792):537-9. DOI: 10.1016/0140-6736(92)90348-7. View

3.
Antman E, Lau J, Kupelnick B, Mosteller F, CHALMERS T . A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA. 1992; 268(2):240-8. View

4.
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C . Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991; 337(8756):1521-6. DOI: 10.1016/0140-6736(91)93206-o. View

5.
. Clinical trial of nimodipine in acute ischemic stroke. The American Nimodipine Study Group. Stroke. 1992; 23(1):3-8. DOI: 10.1161/01.str.23.1.3. View